Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Abstract

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

Description

technical field [0001] The present invention relates to the field of applied medicine, i.e. to displaying neurotropic action, alleviating clinical manifestations of mental disorders, behavioral disorders, cognitive disorders in the case of organic damage of various origins to the central nervous system combination of pharmaceutical compositions. Background technique [0002] Alzheimer's disease (AD) is a progressive, chronic neurodegenerative disease that usually begins slowly and progressively worsens over time. Among older adults, Alzheimer's disease is the most common cause of dementia. Dementia is the loss of cognitive function (thinking, memory, and reasoning) and behavioral abilities to the extent that it interferes with a person's daily life and activities. In its early stages, memory loss is mild, but in advanced AD, individuals lose the ability to carry on conversations and respond to their environment. If left untreated, AD eventually leads to death. Typical li...

AI Technical Summary

Problems solved by technology

[0005] However, acetylcholinesterase inhibitors such as donepezil, rivastigmine and galantamine will not cure AD or prevent the loss of these abilities at some point in the future

Therefore, there is currently no cure for AD and the inventors' efforts are to find better ways to reverse the disease, delay and prevent its progression